Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / TransCode Therapeutics (RNAZ)

TransCode Therapeutics (RNAZ)

Stage unknownUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$25.0Msum of rounds with a disclosed amount only
Named investors
0
Financing history
1 rounds
  1. Oct 8, 2025
    Funding round · $25.0M (disclosed)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno”
Investors on record
0 edges
No named investor yet.
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Oct 8, 2025
    TransCode Therapeutics (RNAZ) announced Funding round of $25,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company